Aiming for developing better treatments and early diagnostics for cancer patients in China and beyond, Qingzhen Biotech （轻诊科技）was incorporated in 2017 at Hangzhou by Mr Yuanxiao Shi (史元晓) and Mr Zichao Song (宋子超). The current focus of the company is on the validation of novel target of ovarian cancer and the development of related therapeutic and diagnostic monoclonal antibodies.
Due to the extremely heterogeneous nature of cancer, each cancer patients are having unique biochemical profiles. Therefore, it is crucial for each patient to be treated individually. Through close collaboration with world-leading institutes and organisations, Qingzhen Biotech are applying state-of-art technologies to select suitable targets from patient delivered database. These data of targets will then be used to optimise novel antibody-based therapies. We aim to combine the comprehensive cancer genetic analysis with the highly specific monoclonal antibodies to accelerate the development of a range of antibodies and antibody-drug conjugates. The ultimate goal is to develop a truly personalised treatment combination for each cancer patients.
Mr Shi, the President of Zhejiang Dinglong Technology Co., Ltd., has been engaged in the chemical and pharmaceutical industry for over 30 years. He and his company had long-term business cooperation with GlaxoSmithKline, Sanofi, Bayer, Merk and other world-renowned pharmaceutical companies
Graduated from Cardiff Business school, Mr Song was specialised in financial advisory and company management. And he has a passion in the pharmacutical industry. He was a formerly Senior Associate in one of the biggest pharmacutical company in China, Zhejiang Int'l Group (SZ.000411), before join Qingzhen biotech.
Dr Lou was specialised in high throughput human mAb cloning and the identification of mAbs against dsDNA, tumor antigens. His research focus are the function of a library of fully human mAbs against challenging biomarker of human diseases.
1. Discover new targets for antibody-drug conjugates and develop first-in-class ADCs in cancer.
2. Develop platforms to fast-track clinical translation of ADCs.
3. Understand the mechanisms of resistance in ADC-based therapies.
1. Biomarker discovery using next generation sequencing and proteomic approaches
2. High-throughput human monoclonal antibody selection and antibody engineering
Immunology, Vol:15, ISSNW 1672-7681, Pages:746-755
Qingzhen Biotech,
2-3504, Lijing Guoji,
Qian Jiang Shi Ji Cheng,
City of Hangzhou, Zhejiang Province
China, 311215
+86 137 0570 5018
Mr Zichao Song
zc.song@qzbiotech.cn
